Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd (PPBT) is a clinical-stage oncology innovator developing therapies to combat tumor resistance mechanisms. This hub provides investors and researchers with timely updates on the company’s pipeline progress, including its dual inhibitor NT219, CEACAM1-targeting CM24 antibody, and tri-specific antibody platform.
Key resources include: Press releases detailing clinical trial milestones for lead candidates, partnership announcements with pharmaceutical collaborators, and regulatory filings related to drug development. Users will find analysis of preclinical data alongside updates on combination therapy strategies involving immunotherapies.
Bookmark this page to efficiently track PPBT’s advancements in overcoming immune evasion through novel mechanisms like STAT3 inhibition and localized immune activation. Check regularly for new insights into trial designs, biomarker analyses, and strategic initiatives shaping the future of precision oncology.
Purple Biotech (NASDAQ: PPBT) announced a publication in Nature Cancer, revealing insights into cancer cell resistance mechanisms linked to IRS1. The study demonstrated that NT219, a dual inhibitor targeting IRS1/2 and STAT3, combined with anti-EGFR therapy, enhances tumor regression and delays recurrence. The publication outlines how IRS1 phosphorylation influences EGFR inhibition persistence, indicating NT219's potential in overcoming drug resistance. This supports ongoing Phase 1/2 clinical trials of NT219 in treating squamous cell carcinoma of the head and neck and colorectal adenocarcinoma.
Purple Biotech (NASDAQ/TASE: PPBT) announced encouraging results from its ongoing Phase 1b/2 clinical trial of CM24, a monoclonal antibody for advanced cancer treatment. One patient with refractory pancreatic cancer showed a partial response with a 40% reduction in tumor size after two courses of CM24 combined with nivolumab, alongside a 56% decrease in CA19-9 tumor marker levels. The second dose cohort has completed enrollment, and the study is expanding to new U.S. and Israeli sites. Top-line data suggests that CM24 is both safe and potentially effective.
Purple Biotech (PPBT) reported no revenue for the six months ended June 30, 2021, compared to $1 million in the same period of 2020. Operating loss increased by 139% to $10.3 million, driven by rising research and development costs related to ongoing clinical trials for NT219 and CM24. Despite these challenges, the company has a solid financial position with $53.4 million in cash, projected to last through 2024. Initial clinical trial results for NT219 showed promising safety and efficacy, including a complete remission in one patient. The company aims to provide additional trial data later this year.
Purple Biotech (NASDAQ/TASE: PPBT) announced promising initial results from a Phase 1/2 clinical trial of NT219 for advanced solid tumors. As of April 25, 2021, six patients were enrolled, with NT219 demonstrating a favorable safety profile and minimal adverse events. Notably, a patient with refractory gastroesophageal junction cancer achieved a partial response after 22 weeks. This dual inhibitor targets IRS1/2 and STAT3, potentially overcoming drug resistance. The company expects to release further data from higher doses in the latter half of 2021.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage company focused on developing innovative therapies to combat tumor immune evasion and drug resistance, announced its participation in the Jefferies Virtual Healthcare Conference. Management will present on June 4, 2021, at 8:30am EST. The conference occurs from June 1-4, 2021, and allows for one-on-one meetings. Purple Biotech's pipeline includes NT219 and CM24, aimed at treating various cancers. Interested parties can access the live and replay webinars on their official website.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) announced it will present interim data from its ongoing Phase 1/2 clinical trial of NT219 on June 4, 2021, at the ASCO Annual Meeting. NT219 is a dual inhibitor targeting IRS1/2 and STAT3, being evaluated as a monotherapy and in combination with cetuximab for advanced solid tumors, including head and neck cancer. The company anticipates further top-line data in the second half of 2021, showcasing its commitment to developing therapies that address tumor immune evasion and drug resistance.
Purple Biotech has appointed Suzana Nahum-Zilberberg to its Board of Directors, enhancing its leadership team. Nahum-Zilberberg, a seasoned biopharmaceutical executive, aims to leverage her operational expertise to advance the company's anti-cancer product candidates, NT219 and CM24. Dr. Eric Rowinsky, the Board Chairman, expressed excitement about her addition, highlighting the importance of her background in driving the company's mission to develop impactful therapeutics. Purple Biotech's pipeline includes innovative therapies targeting tumor immune evasion and drug resistance, with ongoing clinical studies and partnerships with major firms.
Purple Biotech (Nasdaq/TASE: PPBT) announced the first patient has been dosed in a Phase 1b/2 clinical trial of CM24, a monoclonal antibody targeting CEACAM1, in combination with nivolumab for advanced cancer patients. The trial focuses on non-small cell lung cancer (NSCLC) and pancreatic cancer. Preliminary data is expected in the second half of 2021. The trial will assess safety, pharmacokinetics, and efficacy, with multiple sites planned across the U.S., E.U., and Israel. This collaboration with Bristol Myers Squibb marks a significant step in the development of CM24.
Purple Biotech announced additional preclinical data for NT219, a dual inhibitor targeting IRS1/2 and STAT3, presented at the AACR 2021 Meeting. The study analyzed over 16,000 CRC samples, revealing IRS2 amplification in brain metastases. In vitro results showed that NT219 reduced viability in IRS2-expressing cells. The combination of NT219 with 5-FU significantly inhibited brain metastasis formation in an animal model. The ongoing Phase 1/2 trial for NT219 will continue as planned, with top-line data expected in H2 2021.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) has initiated a Phase 1b/2 clinical trial for its monoclonal antibody CM24, aimed at treating advanced cancer patients. This trial, conducted in collaboration with Bristol Myers Squibb, will focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. Preliminary results are expected in the second half of 2021. CM24 demonstrated a 33% disease control rate in previous studies, showing promise in targeting CEACAM1, a key immune checkpoint protein.
